This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kushner, B. H. Articles by Cheung, N.-K. V. Search for Related Content PubMed PubMed Citation Articles by Kushner, B. H. Articles by Cheung, N.-K. V.

Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma

Brian H. Kushner, Kim Kramer, Shakeel Modak, Nai-Kong V. Cheung

From the Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY

Address reprint requests to Brian H. Kushner, MD, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; e-mail: kushnerb{at}mskcc.org

Purpose: To report on an irinotecan and temozolomide regimen for neuroblastoma (NB). Quality of life and minimizing toxicity were major considerations.

Patients and Methods: The plan stipulated 5-day courses of irinotecan 50 mg/m² (1-hour infusion) and temozolomide 150 mg/m² (oral) every 3 to 4 weeks, with a pretreatment platelet count more than 30,000/µL. Granulocyte colony-stimulating factor was used when the absolute neutrophil count was less than 1,000/µL.

Results: Forty-nine NB patients received 1 to 15 courses (median, 5). Gastrointestinal and myelosuppressive toxicities were readily managed. Lymphocyte responses to phytohemagglutinin after 2 to 10 courses (median, 3.5) were normal in 10 of 10 patients treated after nonimmunosuppressive therapy, and normalized in five of seven patients first treated less than 2 months after high-dose alkylators. Of 19 patients treated for refractory NB and assessable for response, nine showed evidence of disease regression, including two complete responses and seven objective responses. Of 17 patients treated for progressive disease, three showed evidence of disease regression, including one partial response and two objective responses. Multiple courses entailed no cumulative toxicity and controlled disease for prolonged periods in many patients, including some who were unable to complete prior treatments because of hematologic, infectious, cardiac, or renal problems.

Conclusion: This regimen has anti-NB activity, spares vital organs, is feasible with poor bone marrow reserve, causes limited immunosuppression, and allows good quality of life.

Supported by grants from the National Cancer Institute (CA61017, CA72868), Bethesda, MD; Hope St Kids, Alexandria, VA; the Justin Zahn Fund, New York, NY; the Katie's Find A Cure Fund, New York, NY; and the Robert Steel Foundation, New York, NY.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				L. M. Wagner, R. E. McLendon, K. J. Yoon, B. D. Weiss, C. A. Billups, and M. K. Danks Targeting Methylguanine-DNA Methyltransferase in the Treatment of Neuroblastoma Clin. Cancer Res., September 15, 2007; 13(18): 5418 - 5425. [Abstract] [Full Text] [PDF]